ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non-Small-Cell Lung Cancer: A Multi-Center Retrospective Study

Chen, Min; Huang, Wenqi; Yang, Dongyong; Huang, Jincheng; Li, Gong; Wang, Xiaoqing; Xiao, Nanjie; Zhang, Weijian; Guan, Jian*; Wang, Shuang*; Liu, Laiyu*广东省人民医院; 北京大学; 南方医科大学; 1
Frontiers in Molecular Biosciences2021-10-8DOI: 10.3389/fmolb.2021.684661
5阅读
引用收藏
分享

摘要

Purpose: This multi-center retrospective study determines whether the & UDelta;CT value of the Amplified Refractory Mutation System (ARMS) predicts the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant advanced non-small-cell lung cancer (NSCLC). @@@ @@@ Patients and methods: Patients who harbored an exon 19 deletion (19Del) or L858R mutation detected by the ARMS and previously received treatment of EGFR-TKIs as a monotherapy were enrolled. A total of 108 NSCLC patients in four hospitals were enrolled. We divided the patients into a high & UDelta;CT group (Group H) and a low & UDelta;CT group (Group L) by the Martingale residuals analysis and log-rank test. The primary outcome was progression-free survival (PFS). Univariate analysis and multivariable regression were applied to compare the PFS between the groups. @@@ @@@ Result: The Martingale residuals analysis and log-rank test were applied to find the cutoff & UDelta;CT value (0.8). In the 108 patients we enrolled, 59 were in group L and 49 were in group H. Patients' demographics and clinical characteristics, including age, sex, smoking history, pathology, mutation sites, TNM stage, and line of TKIs therapy, were not significantly different between group L and group H. The median PFS was 11.1 months in group L and 6.9 months in group H, and the difference showed statistical significance (p < 0.001). Moreover, the objective response rates (ORRs) in group L was significantly higher than in group H (61.0 vs 34.7%, p = 0.002). The median OS was 25.0 months in group L and 20.0 months in group H (p = 0.046). @@@ @@@ Conclusion: The & UDelta;CT value of ARMS could be an efficacy predictor for EGFR-TKI treatment in advanced EGFR-mutant NSCLC.

学科与关键词

关键词
Delta CTARMSefficacyEGFR-TKIsNSCLC
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Molecular Biosciences
发表日期
2021-10-08
卷期
第 8 卷
页码
684661
DOI
10.3389/fmolb.2021.684661
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81870026]; Clinical Research Startup Program of Southern Medical University [LC2016PY015, LC2019ZD008]; Clinical Research Program of Nanfang Hospital, Southern Medical University [2018CR019, 2018CR021, 2020CR025]

作者

  • C

    Chen, Min (第一作者)

    southern med univ · peking univ shenzhen

  • H

    Huang, Wenqi

    southern med univ

查看全部 11 位作者收起作者
  • Y

    Yang, Dongyong

    2 · fujian med univ

  • H

    Huang, Jincheng

    2 · fujian med univ

  • L

    Li, Gong

    guangdong prov hosp

  • W

    Wang, Xiaoqing

    southern med univ

  • X

    Xiao, Nanjie

    southern med univ

  • Z

    Zhang, Weijian

    1 · fujian med univ

  • G

    Guan, Jian (通讯)

    southern med univ

  • W

    Wang, Shuang (通讯)

    southern med univ

  • L

    Liu, Laiyu (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417